INSURASALES

Tag: Drug Pricing

Trump Administration to Reintroduce 'Most Favored Nation' Drug Pricing for Medicare

The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.

Pharma Firms Boost Consumer Drug Ads Amid Tax Benefits Concerns

Pharmaceutical companies increased consumer-directed drug advertising by nearly 30% in early 2025, leveraging tax deductions that affect prescription drug prices, according to AHIP and CSRxP analyses.

CMS Final Rule Advances Medicare Drug Price Negotiation Program for 2026

CMS's 2026 Final Rule implements the Medicare Drug Price Negotiation Program with the Medicare Transaction Facilitator, affecting Part D drug pricing and pharmacy reimbursement processes.

U.S. Health Policy Update: Autism Research, Drug Pricing, HHS Cuts, and Preventive Care Coverage

Insights on recent shifts in U.S. health policy: autism research, drug pricing reforms, HHS operational cuts, abortion access, and legal challenges to insurance preventive care coverage.

Medicare Drug Coverage and Costs for Jardiance in Heart Failure and Diabetes Care

Explore how Medicare Part D and C plans cover Jardiance for heart failure and type 2 diabetes, including costs, formularies, and pricing reforms under the Inflation Reduction Act.

Medicare Drug Cost Sharing Shifts Drive Higher Patient Expenses

Medicare beneficiaries face higher costs as Part D plans shift from fixed co-pays to coinsurance for expensive Tier 3 drugs, raising out-of-pocket expenses significantly.

Trump Executive Order on Drug Pricing Targets Medicare, 340B Reimbursements

Summary of Trump's executive order directing HHS to reduce prescription drug costs, focusing on Medicare reimbursement for 340B drugs, IRA drug pricing provisions, and CMS premium stabilization efforts.